Ribon Therapeutics ribontx.com


Public list: Pharma Startups (6570) Cancer Therapeutics (1180)

Ribon Therapeutics is targeting the discovery and development of monoPARP (mono ADP-ribose polymerase) inhibitors to block cancer cells' fundamental ability to survive under stress.

Ribon Therapeutics is targeting the discovery and development of monoPARP (mono ADP-ribose polymerase) inhibitors to block cancer cells' fundamental ability to survive under stress.

Company (Alive / Active)

Phone: 617-914-8700

Fax:

99 Hayden Avenue

Lexington, 02421
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Ribon Therapeutics $98.5M Jan 4, 2019

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Ribon Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 12 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Quinazolinones as parp14 inhibitors Dec 20, 2018 Feb 18, 2020 Patent
Pyridazinones as parp7 inhibitors Apr 29, 2019 Feb 04, 2020 Patent
Quinazolinones as parp14 inhibitors Jan 06, 2020 Application
Pyridazinones as parp7 inhibitors Oct 24, 2019 Application
Screening methods for parp modulators Apr 29, 2019 Application